Abstract：
OBJECTIVE: Intravitreal dexamethasone implant (IID) is an effective and safe treatment for macular oedema as described in the literature. Ocular hypertension and cataracts are the most frequent complications. The indications of IID in the last few years have led to the retrospective reporting of rare complications, with potential visual impact related to the injection procedure.
METHODS: A case series is presented of fifteen patients treated with IID for macular oedema who developed non-pharmacological complications related to the injection procedure or the implant itself, including, among others anterior chamber migration, intracrystalline injection, endophthalmitis, or segmentation. Differentiation was made between true complications and those that did not lead to any ocular damage. Epidemiological and baseline data were collected along with the treatment and outcome in each case. An analysis was made of multimodal imaging available.
RESULTS: The incidence of complications was 0.65% in this series Anterior chamber migration was the most frequent complication (n=4), followed by intracrystalline injection, and endophthalmitis (n=2). The times between the injection and complications were variable. Visual impairment was the most common symptom (n=6). However, despite the complications found, IID was an effective treatment in most of the reported cases.
CONCLUSIONS: Clinicians should be aware of these rare non-pharmacological complications so that they may be prevented and detected early, avoiding irreversible ocular damage.
METHODS: A case series is presented of fifteen patients treated with IID for macular oedema who developed non-pharmacological complications related to the injection procedure or the implant itself, including, among others anterior chamber migration, intracrystalline injection, endophthalmitis, or segmentation. Differentiation was made between true complications and those that did not lead to any ocular damage. Epidemiological and baseline data were collected along with the treatment and outcome in each case. An analysis was made of multimodal imaging available.
RESULTS: The incidence of complications was 0.65% in this series Anterior chamber migration was the most frequent complication (n=4), followed by intracrystalline injection, and endophthalmitis (n=2). The times between the injection and complications were variable. Visual impairment was the most common symptom (n=6). However, despite the complications found, IID was an effective treatment in most of the reported cases.
CONCLUSIONS: Clinicians should be aware of these rare non-pharmacological complications so that they may be prevented and detected early, avoiding irreversible ocular damage.
摘要：
目的：玻璃体腔注射地塞米松（IID）是一种有效且安全的治疗黄斑水肿的方法，如文献所述。眼部高血压和白内障是最常见的并发症。在过去的几年中，IID的适应症导致了罕见并发症的回顾性报告，与注射程序相关的潜在视觉冲击。
方法：提供了一个病例系列，包括15例使用IID治疗黄斑水肿的患者，这些患者出现了与注射程序或植入物本身相关的非药物并发症，包括,在其他前房迁移中，晶体内注射，眼内炎,或分段。在真正的并发症和没有导致任何眼部损伤的并发症之间进行了区分。收集流行病学和基线数据以及每种情况下的治疗和结果。对可用的多模态成像进行了分析。
结果：本系列并发症发生率为0.65%。前房迁移是最常见的并发症（n=4），然后是晶体内注射，和眼内炎（n=2）。注射和并发症之间的时间是可变的。视力障碍是最常见的症状（n=6）。然而,尽管发现了并发症，在大多数报告的病例中，IID是一种有效的治疗方法。
结论：临床医生应注意这些罕见的非药物并发症，以便及早预防和发现，避免不可逆的眼部损伤。
方法：提供了一个病例系列，包括15例使用IID治疗黄斑水肿的患者，这些患者出现了与注射程序或植入物本身相关的非药物并发症，包括,在其他前房迁移中，晶体内注射，眼内炎,或分段。在真正的并发症和没有导致任何眼部损伤的并发症之间进行了区分。收集流行病学和基线数据以及每种情况下的治疗和结果。对可用的多模态成像进行了分析。
结果：本系列并发症发生率为0.65%。前房迁移是最常见的并发症（n=4），然后是晶体内注射，和眼内炎（n=2）。注射和并发症之间的时间是可变的。视力障碍是最常见的症状（n=6）。然而,尽管发现了并发症，在大多数报告的病例中，IID是一种有效的治疗方法。
结论：临床医生应注意这些罕见的非药物并发症，以便及早预防和发现，避免不可逆的眼部损伤。
